MEASUREMENTS OF RETINAL FLUID BY OPTICAL COHERENCE TOMOGRAPHY LEAKAGE IN DIABETIC MACULAR EDEMA: A Biomarker of Visual Acuity Response to Treatment
- PMID: 29077605
- DOI: 10.1097/IAE.0000000000001905
MEASUREMENTS OF RETINAL FLUID BY OPTICAL COHERENCE TOMOGRAPHY LEAKAGE IN DIABETIC MACULAR EDEMA: A Biomarker of Visual Acuity Response to Treatment
Abstract
Purpose: To evaluate the effects of anti-vascular endothelial growth factor treatment on retinal fluid in patients with diabetic macular edema by using optical coherence tomography leakage (OCT-L), a new method of quantifying sites of lower than normal optical reflectivity (LOR) in OCT, and to correlate these findings with best-corrected visual acuity (BCVA) response.
Methods: Prospective analysis of 21 eyes with diabetic macular edema, naive to anti-vascular endothelial growth factor treatment. Macular cube 512 × 128 and OCT angiography 6 × 6-mm scans (CIRRUS AngioPlex; ZEISS, Dublin, CA) were acquired in all eyes before the first ranibizumab injection (V1) and 1 week after treatment (V2). Optical coherence tomography leakage analysis was performed with Angioplex raw scan data used to calculate LOR map ratios. Lower optical reflectivity ratios at baseline and differences from V1 to V2 and other OCT morphological features such as central retinal thickness measurements, disorganization of the inner retinal layers, and disruption of ellipsoid zone were compared with BCVA response 1 month after the first intravitreal injection.
Results: After the first intravitreal injection of ranibizumab, eight patients (38%) were identified as good responders, 5 (24%) as moderate, and 8 (38%) as poor. There were no significant BCVA differences at baseline. Significant differences were found in LOR ratio changes between the different treatment response groups after 1 week of treatment, especially in outer segment and outer plexiform layer (outer segment-good responders: -53%, responders: -12%, and poor responders: 7% [P = 0.026]; outer plexiform layer-good responders: -49%, responders: 18%, and poor responders: 5% [P = 0.010]). Lower optical reflectivity ratios differences after 1 week of treatment predict better the BCVA treatment response at 1 month than changes of central retinal thickness, disorganization of the inner retinal layer, and ellipsoid zone disruption, especially in the outer segment and outer plexiform layer (area under the curve = 0.82 and 0.73, respectively).
Conclusion: Optical coherence tomography leakage changes after anti-vascular endothelial growth factor treatment of diabetic macular edema, identifying the degree of decrease in retinal fluid in the outer layers of the retina is a more robust biomarker of BCVA recovery than central retinal thickness, disorganization of the inner retinal layer, or ellipsoid zone disruption changes.
Similar articles
-
IMPACT OF LONG-TERM INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR ON PREEXISTING MICROSTRUCTURAL ALTERATIONS IN DIABETIC MACULAR EDEMA.Retina. 2018 Sep;38(9):1824-1829. doi: 10.1097/IAE.0000000000001788. Retina. 2018. PMID: 28767550
-
OCT Angiography Biomarkers for Predicting Visual Outcomes after Ranibizumab Treatment for Diabetic Macular Edema.Ophthalmol Retina. 2019 Oct;3(10):826-834. doi: 10.1016/j.oret.2019.04.027. Epub 2019 May 7. Ophthalmol Retina. 2019. PMID: 31227330 Free PMC article.
-
OPTICAL COHERENCE TOMOGRAPHY LEAKAGE IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Identification of Choroidal Neovascularization Activity by Location and Quantification of Abnormal Fluid Under Anti-Vascular Endothelial Growth Factor Therapy.Retina. 2020 May;40(5):881-890. doi: 10.1097/IAE.0000000000002470. Retina. 2020. PMID: 30689620 Free PMC article.
-
Ranibizumab in Diabetic Retinopathy with or without Diabetic Macular Edema.Ophthalmol Retina. 2020 Oct;4(10):1034-1036. doi: 10.1016/j.oret.2020.05.020. Epub 2020 Jun 5. Ophthalmol Retina. 2020. PMID: 32512056 Review. No abstract available.
-
Predicting outcomes to anti-vascular endothelial growth factor (VEGF) therapy in diabetic macular oedema: a review of the literature.Br J Ophthalmol. 2016 Dec;100(12):1596-1604. doi: 10.1136/bjophthalmol-2016-308388. Epub 2016 May 26. Br J Ophthalmol. 2016. PMID: 27231313 Review.
Cited by
-
Imaging Features of Vessels and Leakage Patterns Predict Extended Interval Aflibercept Dosing Using Ultra-Widefield Angiography in Retinal Vascular Disease: Findings From the PERMEATE Study.IEEE Trans Biomed Eng. 2021 Jun;68(6):1777-1786. doi: 10.1109/TBME.2020.3018464. Epub 2021 May 21. IEEE Trans Biomed Eng. 2021. PMID: 32822291 Free PMC article. Clinical Trial.
-
Efficacy and safety profile of intravitreal dexamethasone implant versus antivascular endothelial growth factor treatment in diabetic macular edema: a systematic review and meta-analysis.Sci Rep. 2023 May 8;13(1):7428. doi: 10.1038/s41598-023-34673-z. Sci Rep. 2023. PMID: 37156823 Free PMC article.
-
Flavoprotein Fluorescence Correlation with Visual Acuity Response in Patients Receiving Anti-VEGF Injection for Diabetic Macular Edema.Oxid Med Cell Longev. 2018 Aug 9;2018:3567306. doi: 10.1155/2018/3567306. eCollection 2018. Oxid Med Cell Longev. 2018. PMID: 30159113 Free PMC article.
-
Retinal Fluid Volatility Associated With Interval Tolerance and Visual Outcomes in Diabetic Macular Edema in the VISTA Phase III Trial.Am J Ophthalmol. 2021 Apr;224:217-227. doi: 10.1016/j.ajo.2020.11.010. Epub 2020 Nov 28. Am J Ophthalmol. 2021. PMID: 33253664 Free PMC article. Clinical Trial.
-
The Area and Number of Intraretinal Cystoid Spaces Predict the Visual Outcome after Ranibizumab Monotherapy in Diabetic Macular Edema.J Clin Med. 2020 May 8;9(5):1391. doi: 10.3390/jcm9051391. J Clin Med. 2020. PMID: 32397232 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials